Chris Compton
Overview
Explore the profile of Chris Compton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
499
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Haeussler K, Ismaila A, Malmenas M, Noorduyn S, Green N, Compton C, et al.
Respir Res
. 2024 Dec;
25(1):438.
PMID: 39709425
To optimize patient outcomes, healthcare decisions should be based on the most up-to-date high-quality evidence. Randomized controlled trials (RCTs) are vital for demonstrating the efficacy of interventions; however, information on...
2.
Singh D, Han M, Bhatt S, Miravitlles M, Compton C, Kolterer S, et al.
Am J Respir Crit Care Med
. 2024 Dec;
211(3):452-463.
PMID: 39680953
Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition characterized by progressive airflow obstruction. Despite advancements in diagnosis and treatment, the disease burden remains high; although clinical trials have...
3.
Joksaite S, Wood R, Ismaila A, Camidge L, Mizukami A, Czira A, et al.
BMJ Open
. 2024 Dec;
14(12):e080864.
PMID: 39632104
Objectives: To evaluate and compare medication adherence and persistence for patients newly initiating single-inhaler triple therapy (SITT) and multiple-inhaler triple therapy (MITT) for chronic obstructive pulmonary disease (COPD) in Japan....
4.
Vogelmeier C, Beeh K, Kardos P, Paulsson T, Rohde G, Watz H, et al.
Ther Adv Respir Dis
. 2024 Oct;
18():17534666241287621.
PMID: 39436955
Background: Evidence on how decisions regarding escalation to triple therapy and de- or re-escalation are taken and the rationale on which these decisions are based is currently limited in Germany....
5.
Vogelmeier C, Beeh K, Schultze M, Kossack N, Richter L, Claussen J, et al.
Int J Chron Obstruct Pulmon Dis
. 2024 Aug;
19:1835-1848.
PMID: 39140078
Purpose: Triple therapy (long-acting muscarinic antagonist/long-acting β-agonist/inhaled corticosteroid) is recommended for patients with chronic obstructive pulmonary disease (COPD) who experience recurrent exacerbations. Multiple-inhaler triple therapy (MITT) is associated with poor...
6.
Wang Y, Vallee E, Heuer C, Wang Y, Guo A, Zhang Z, et al.
One Health
. 2024 Jul;
18:100683.
PMID: 39010971
Brucellosis, caused by spp., is a re-emerging One Health disease with increased prevalence and incidence in Chinese dairy cattle and humans, severely affecting animal productivity and public health. In dairy...
7.
Rothnie K, Wood R, Czira A, Banks V, Camidge L, Massey O, et al.
BMJ Open Respir Res
. 2024 May;
11(1).
PMID: 38772900
Background: Compared with multiple-inhaler triple therapy (MITT), single-inhaler triple therapy (SITT) with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) demonstrated improved lung function and meaningful improvements in chronic obstructive pulmonary disease (COPD) Assessment Test...
8.
Beeh K, Rothnie K, Claussen J, Hardtstock F, Knapp R, Wilke T, et al.
Int J Chron Obstruct Pulmon Dis
. 2024 Apr;
19:945-956.
PMID: 38646606
Purpose: To assess patient characteristics of users and new initiators of triple therapy for chronic obstructive pulmonary disease (COPD) in Germany. Patients And Methods: Retrospective cohort study of patients with...
9.
Ismaila A, Rothnie K, Wood R, Banks V, Camidge L, Czira A, et al.
Respir Res
. 2024 Apr;
25(1):152.
PMID: 38561735
No abstract available.
10.
Aggarwal B, Jones P, Casas A, Gomes M, Juthong S, Litewka D, et al.
Pulm Ther
. 2024 Mar;
10(2):183-192.
PMID: 38446336
Introduction: Despite the proven benefits of inhaled corticosteroid (ICS)-containing triple therapy for chronic obstructive pulmonary disease (COPD), clinicians limit patient exposure to ICS due to the risk of pneumonia. However,...